HEIDELBERG, Germany–(BUSINESS WIRE)–Heidelberg Engineering and Gauss Medical Corporation Establish an Ophthalmic Healthcare IT Joint Venture in China
Stem cell research offers new hope of restoring sight
As the population ages, retinal degeneration becomes more prevalent. Stem cell research inches closer to a future where vision loss may be reversible.
First US Service Members Treated with the Only FDA-Approved Cross-Linking Procedure in the U.S.
WALTHAM, Mass.–(BUSINESS WIRE)–#avedro–Avedro, Inc., an ophthalmic pharmaceutical and medical device company, has begun selling Photrexa Viscous® (riboflavin 5-‘phosphate in 20% dextran ophthalmic solution), Photrexa® (riboflavin 5’-phosphate ophthalmic solution) and the KXL® System to key military hospitals around the country. Fort Belvoir Hospital, located in Fort Belvoir, VA, made history on November 21st to become the first military facility in the country to perform FDA-approved corneal cross-li
IACTA Pharmaceuticals Licenses NM133 from Nanomerics for Treatment of Dry Eye
NEWPORT BEACH, Calif.–(BUSINESS WIRE)–IACTA Pharmaceuticals has acquired the North American rights to develop and commercialize NM133, an investigational medicine designed to help treat dry eye from its developer, Nanomerics, Ltd.
NOACs Linked to Higher Risk of Intraocular Bleeding
Some new oral anticoagulants (NOACs) are associated with an increased risk of intraocular hemorrhage, according to a new analysis of World Health Organization (WHO) data. Reuters Health Information
Uncategorized
Ivantis secures $25 million in funding for commercialization of Hydrus microstent
Ivantis has secured $25 million in Series C funding for U.S. commercialization of the Hydrus microstent, according to a company press release.The Hydrus microstent, which is about the size of an eyelash, is expected to be approved by the FDA in 2018, the release said. It is designed to reduce a glaucoma patient’s IOP by re-establishing the natural outflow pathway, which is done through a minimally invasive microsurgical procedure.